Wall Street brokerages expect Accuray Incorporated (NASDAQ:ARAY) to report earnings per share (EPS) of ($0.11) for the current quarter, according to Zacks. Two analysts have made estimates for Accuray’s earnings, with estimates ranging from ($0.11) to ($0.10). Accuray also reported earnings of ($0.11) per share during the same quarter last year. The firm is scheduled to announce its next earnings results on Tuesday, January 30th.

On average, analysts expect that Accuray will report full year earnings of ($0.20) per share for the current fiscal year, with EPS estimates ranging from ($0.24) to ($0.15). For the next financial year, analysts expect that the firm will report earnings of ($0.11) per share, with EPS estimates ranging from ($0.12) to ($0.10). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Accuray.

Accuray (NASDAQ:ARAY) last released its earnings results on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.02. Accuray had a negative net margin of 7.49% and a negative return on equity of 55.18%. The firm had revenue of $91.00 million during the quarter, compared to analyst estimates of $88.26 million. During the same quarter in the previous year, the firm earned ($0.12) earnings per share. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year.

Several research firms have weighed in on ARAY. J P Morgan Chase & Co lowered shares of Accuray from a “neutral” rating to an “underweight” rating and set a $6.00 target price for the company. in a research note on Wednesday, December 13th. BidaskClub lowered shares of Accuray from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Lake Street Capital began coverage on shares of Accuray in a research report on Thursday, November 30th. They set a “buy” rating and a $10.00 price target for the company. Cowen restated a “buy” rating and set a $9.00 price target on shares of Accuray in a research report on Friday, October 27th. Finally, Zacks Investment Research lowered shares of Accuray from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. Accuray has a consensus rating of “Hold” and an average target price of $6.82.

Shares of Accuray (NASDAQ:ARAY) opened at $4.05 on Wednesday. The company has a debt-to-equity ratio of 2.44, a current ratio of 1.48 and a quick ratio of 0.92. Accuray has a 12 month low of $3.60 and a 12 month high of $6.00.

In other news, COO Kelly Londy sold 99,136 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $4.24, for a total transaction of $420,336.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Kevin Waters sold 7,154 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $5.06, for a total transaction of $36,199.24. Following the transaction, the chief financial officer now owns 335,087 shares of the company’s stock, valued at approximately $1,695,540.22. The disclosure for this sale can be found here. Insiders have sold 125,549 shares of company stock valued at $550,135 in the last 90 days. Insiders own 3.90% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Accuray by 4.4% in the second quarter. Vanguard Group Inc. now owns 6,728,919 shares of the medical equipment provider’s stock worth $31,962,000 after purchasing an additional 281,789 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Accuray by 27.6% in the first quarter. Dimensional Fund Advisors LP now owns 858,013 shares of the medical equipment provider’s stock worth $4,076,000 after purchasing an additional 185,519 shares during the period. Renaissance Technologies LLC lifted its holdings in Accuray by 2.0% in the second quarter. Renaissance Technologies LLC now owns 4,391,000 shares of the medical equipment provider’s stock worth $20,857,000 after purchasing an additional 85,400 shares during the period. Northern Trust Corp lifted its holdings in Accuray by 4.5% in the second quarter. Northern Trust Corp now owns 1,048,694 shares of the medical equipment provider’s stock worth $4,981,000 after purchasing an additional 45,134 shares during the period. Finally, PDT Partners LLC lifted its holdings in Accuray by 60.5% in the second quarter. PDT Partners LLC now owns 156,500 shares of the medical equipment provider’s stock worth $743,000 after purchasing an additional 58,985 shares during the period. 78.86% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/0-11-eps-expected-for-accuray-incorporated-aray-this-quarter/1774223.html.

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Get a free copy of the Zacks research report on Accuray (ARAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.